Novo Nordisk, the Danish company behind the breakthrough GLP-1 treatment 'Ozempic,' operates under a 'foundation ownership model'—meaning that the majority of the company's voting power is held by a foundation, while the majority of the equity is owned by public investors.

Can you microdose GLP-1 agonists like Ozempic?

GLP-1 agonists like Ozempic can help with weight loss, diabetes, and anti-inflammation. For some users, normal doses are too much. So, they've started "microdosing"—taking a smaller amount than the lowest increment of the drug available. While not yet backed by clinical trials, some doctors observed positive effects for certain people.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

GLP-1 drugs mimic a natural hormone that triggers appetite-suppressing effects

Ozempic, one of the brand names for the drug semaglutide, was originally developed in 2012, to help treat Type 2 diabetes. Among other effects, the drug mimics a naturally produced hormone known as GLP-1, which is released while eating to let our bodies know we are full.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

Research suggests Ozempic has benefits beyond weight loss

Semaglutide, the key ingredient in Ozempic, is proving to be more than just a diabetes and weight loss drug. Research suggests it may also help prevent strokes, improve heart health, and slow Alzheimer’s.

The popularity of new weight loss drugs has led to a diabetes treatment shortage

The FDA approved Ozempic to help patients with diabetes, but the popularity of semaglutide as a weight loss drug led doctors to prescribe Ozempic to nondiabetic patients who needed to lose weight. Ozempic became so popular that manufacturers could not keep pace with demand, posing risks for Ozempic-users with diabetes.

How self-care led to Ozempic's success

Self-care has become a $1.5T economy that idealizes restraint and willpower, leaving behind those who can't shake off human nature. This article explores how Ozempic and similar weight loss medications pick up where self-care left off.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Medicare does not pay for GLP-1 for obesity

Coverage for GLP-1s for obesity treatment is limited. It's barred under Medicare, and it's only covered under Medicaid in 13 states as of January 2026, since states can choose whether to cover weight-loss drugs under Medicaid. Coverage with private insurers also remains limited.

Dual-class stock structures separate equity and decision-making authority

In the past few decades, dual-class stock structures have become an increasingly popular way for companies to raise capital in public markets without allocating traditional shareholder voting rights. Meta, Estée Lauder, and The New York Times are companies that are famously dual-class.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

When people stopped using GLP-1, they regained two-thirds of the weight back

Research from 2022 found that when people stopped using the injectable form of the medication, they regained up to two-thirds of lost weight within a year. The finding suggests ongoing treatment will be required for weight loss.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

From Ozempic to Wegovy, see the $58B weight loss drug market visualized in one chart.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

In 2025, Weight Watchers filed for Chapter 11 bankruptcy after reporting revenue and profit losses for multiple consecutive years, with its stock price losing about 99% of its value between 2018 and 2025.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

Mark Zuckerberg has nearly exclusive decision-making authority in Meta

Meta has a dual-class stock structure, meaning there are two types of stock that have different voting rights. Zuckerberg owns 90% of the company's Class B stock, which is allotted 10 votes per share, whereas Class A shareholders get one vote per share. He's also the CEO and the chairman of the board, meaning Zuckerberg has majority control over the company. (Some users may experience a paywall.)

Talk show host Oprah Winfrey spent about $43M in 2015 to buy a 10% stake in Weight Watchers and join its board of directors, going on to lose 40lbs using the program.

Should companies be owned by their workers?

In the last half-century, so-called private equity has transformed industries by purchasing private companies, cutting costs, loading up debt, and then selling the business at a premium—all at a huge profit to the investors. Workers, on the other hand, are often left with nothing. Listen to how both pro-worker economists and a private equity stalwart are trying to shift ownership to workers—a growing tactic proven to improve worker satisfaction and company value.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

Coca-Cola operates under an asset-light, divided structure

The "company" manages the brand itself, as well as its secret formula and syrup production. The capital-intensive "system" of independent bottlers, on the other hand, handles manufacturing and distribution.

Some Ozempic users lose their desire to eat

This essay follows a writer whose Ozempic journey involves a dramatic loss of appetite, leading them to stop compulsive snacking and even lose some of the joy of eating. As a result, he becomes fixated on watching food videos and eventually tries to "beat" an all-you-can-eat steak buffet. The experience leaves him feeling disappointed and lacking in desire.

Activist investors use large ownership positions to influence companies

By holding large ownership positions, which often come with leveraged access to a company's board or the ability to force a shareholder vote, activist shareholders can change a company's corporate governance, leadership, and overall direction. Critics argue that activist shareholders hurt companies in the long term by prioritizing short-term higher shareholder returns over sustainability and growth efforts.

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva.

The Lauder family still owns more than 80% of Estée Lauder Companies

When Estée Lauder went public in 1995, the company implemented a dual-class stock structure to retain family ownership of the company. Alongside owning a majority of the stock, almost everyone in the family also works within the company, leading to the family's reputation as a cosmetic dynasty.

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

Semaglutides, which belong to a class of drugs called GLP-1s, are prescribed for weight loss in combination with diet and exercise because they trigger the release of the appetite-suppressing hormone incretin.

Companies go public via an initial public offering (IPO) to raise large amounts of capital, helping them expand, invest in new ventures, hire more staff, or pay off debts.